Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors

Summary

This is a single-group, open, dose escalation and expansion Phase I clinical study, with phase I being a dose escalation study and Phase II being a dose expansion study. The purpose of this study was to evaluate the safety and tolerability of TQB2825 injection in CD20-positive hematological tumor subjects, and to determine dose-limiting toxicity (DLT), maximum tolerated dose (MTD) (if any), or optimal biological dose (OBD), and recommended phase II dose (RP2D).

Timeline

Start

2022-03-22

Primary completion

2023-10

Completion

2023-12

Drugs

Indications